

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Clover Biopharmaceuticals, Ltd.

三葉草生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2197)

**VOLUNTARY ANNOUNCEMENT
CLOVER'S VACCINE CANDIDATE REDUCED
HOUSEHOLD TRANSMISSION OF SARS-COV-2 BY 84%
IN STUDY PUBLISHED IN CLINICAL INFECTIOUS DISEASES**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Clover Biopharmaceuticals, Ltd. (the “**Company**” or “**Clover**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors on the latest clinical development status of the core product of the Group.

The Company is pleased to announce that *Clinical Infectious Diseases* has published additional data from SPECTRA (Study Evaluating Protective Efficacy and Safety of the Company’s Trimeric Recombinant Protein-based and Adjuvanted COVID-19 Vaccine), a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

The study demonstrated that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 (CpG 1018/Alum), compared to households where the infected household member was not vaccinated. Among the 134 household contacts of infected household members who had received SCB-2019 (CpG 1018/Alum), there was one case of COVID-19; among the 250 household contacts of infected household members who were not vaccinated, there were 12 cases.

There were no cases of symptomatic SARS-CoV-2 infection among household contacts who were partially or fully vaccinated and where the infected household member was vaccinated with SCB-2019 (CpG 1018/Alum). This indicates that SCB-2019 (CpG 1018/Alum) vaccination reduced household transmission and that vaccinated household contacts also likely benefited from the protection provided by their own vaccination.

This exploratory, prospective study was part of the SPECTRA Phase 2/3 trial and compared reductions in SARS-CoV-2 infections in households and household contacts of SCB-2019 (CpG 1018/Alum) vaccine recipients with infections in households and household contacts of placebo recipients. The study was performed at eight Phase 2/3 SPECTRA sites in the Philippines. A total of 154 participants who received placebo or SCB-2019 (CpG 1018/Alum) and who subsequently experienced SARS-CoV-2 infection were enrolled in this study as were 388 of their household contacts. The study team was blinded to the assignment of SPECTRA participants to vaccine or placebo groups. Enrolled households and household contacts were monitored for three weeks to detect new COVID-19 infections. Symptomatic cases for participants and household contacts were confirmed with reverse transcriptase polymerase chain reaction (rRT-PCR) test, while asymptomatic cases were determined using anti-N antibody rapid antibody test kits.

The Company is working towards completing regulatory submissions to National Medical Products Administration (國家藥品監督管理局) of China, the European Medicines Agency, and the World Health Organization for SCB-2019 (CpG 1018/Alum) by the end of 2022, while concurrently preparing for its commercialization in China and globally upon receiving regulatory approvals.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to ultimately commercialize SCB-2019 (CpG 1018/Alum) successfully.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Clover Biopharmaceuticals, Ltd.
Dr. Peng LIANG
Chairman of the Board

Shanghai, PRC, November 30, 2022

As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG, Dr. Donna Marie AMBROSINO and Dr. Ralf Leo CLEMENS as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.